Cardinal Health, Inc. has announced its first-quarter results for fiscal year 2027, showcasing a solid performance that reflects the company's strategic focus on growth and efficiency. The results, released on November 5, 2026, indicate a 5% increase in revenue, reaching $67.5 billion. Additionally, the company raised its earnings per share (EPS) guidance for the fiscal year, signaling a positive outlook for its future performance.

For the quarter ended September 30, 2026, Cardinal Health reported GAAP operating earnings of $753 million, a 13% increase from the previous year. The GAAP diluted EPS rose 27% to $2.38. Non-GAAP operating earnings also saw significant growth, increasing 17% to $1.0 billion, with non-GAAP diluted EPS climbing 28% to $3.26. This strong performance is attributed to the company's disciplined operations and strategic investments.

Cardinal Health's CEO, Jason Hollar, commented on the results, stating, "Our results reflect a strong start to fiscal 2027 and demonstrate consistent execution against our strategic priorities. We continue to benefit from focused investments, disciplined operations, and the strength of our diversified portfolio." He also noted that the company is raising its fiscal year 2027 non-GAAP EPS guidance to between $12.80 and $13.00, representing a growth rate of 17% to 19% from its fiscal year 2026 baseline.

Background

Cardinal Health, Inc. is a leading provider of pharmaceuticals and medical products, classified under the SIC code 5122, which pertains to wholesale drugs, proprietaries, and druggists' sundries. The company is publicly traded on the New York Stock Exchange under the ticker symbol CAH. With a focus on improving healthcare delivery, Cardinal Health operates in a highly competitive market, serving various healthcare providers and patients across the United States.

What the Filing Says

According to the SEC filing (accession number 0000721371-26-000042), Cardinal Health's revenue for the first quarter of fiscal year 2027 was $67.5 billion. The company reported a GAAP operating earnings increase of 13% to $753 million and a GAAP diluted EPS increase of 27% to $2.38. Additionally, non-GAAP operating earnings increased 17% to $1.0 billion, with non-GAAP diluted EPS rising 28% to $3.26.

Impact

The positive results and raised guidance from Cardinal Health may influence various stakeholders, including investors, healthcare providers, and competitors within the wholesale drugs industry. The company's strong performance may enhance investor confidence and attract potential investors looking for growth opportunities in the healthcare sector.

What's Next

Following this filing, Cardinal Health is expected to continue its focus on executing its strategic priorities and may provide further updates on its performance and outlook in subsequent filings or communications. The filing does not specify what happens next.